{"data":{"id":"us-ky/krs-217.814","jurisdiction":"us-ky","citation":"KRS 217.814","heading":"Definitions for KRS 217.815 to 217.826.","body":"The following words and phrases, as used in KRS 217.815 to 217.826, shall have the\nfollowing meanings, unless the context requires otherwise:\n(1) \"Biological product\" has the same meaning as in 42 U.S.C. sec. 262;\n(2) \"Board\" means the Kentucky Board of Pharmacy;\n(3) \"Brand name\" means the name that a manufacturer of a drug or pharmaceutical\nplaces on the container thereof at the time of packaging;\n(4) \"Dosage formulation\" shall include but not be limited to those specific dosage\nforms which, by the nature of their physical manufacture, are deemed to be\nnonequivalent to other similar formulations such as controlled -release tablets,\naerosol-nebulizer drug delivery systems, and enteric-coated oral dosage forms;\n(5) \"Equivalent drug product\" means a product wit h the same generic name, active\ningredients, strength, quantity, and dosage form as the drug product identified in a\nprescription;\n(6) \"Generic name\" means the chemical or established name of a drug or\npharmaceutical;\n(7) \"Interchangeable biological product\" means:\n(a) A biological product that the United States Food and Drug Administration has\nlicensed and determined meets the standards for interchangeability pursuant to\n42 U.S.C. sec. 262(k)(4); or\n(b) A biological product that the United States Food and Drug Administration has\ndetermined is therapeutically equivalent as set forth in the latest edition or\nsupplement to the federal Food and Drug Administration's Approved Drug\nProducts with Therapeutic Equivalence Evaluations;\n(8) \"Nonequivalent drug product  formulary\" means a formulary of drugs, drug\nproducts, and dosage formulations for which there are no equivalent drugs, drug\nproducts, or dosage formulations and which have been determined to be\nnoninterchangeable or to have actual or potential bioequivale ncy problems by the\nUnited States Food and Drug Administration and are contained in a drug\nbioequivalence problems list as published in the United States Food and Drug\nAdministration publication entitled \"Approved prescription drug products with\ntherapeutic equivalence evaluations\" with supplements;\n(9) \"Pharmacist\" has the same meaning as in KRS 315.010; and\n(10) \"Practitioner\" has the same meaning as in KRS 217.015.","path":["KRS Chapter 217"],"source_url":"https://apps.legislature.ky.gov/law/statutes/statute.aspx?id=45074","current_through":"Includes enactments through the 2026 Regular Session","vintage":"09/05/2026","retrieved_at":"2026-09-05T20:52:27Z","sha256":"8fdb855a9f98d9f0036a263643fc8211b68244ad3683796e10457a6d0b8696a7","source_id":"us-ky","stale":false,"prev":"us-ky/krs-217.813","next":"us-ky/krs-217.815"},"notice":"GroundRules: Original legal text. Not legal advice."}